Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3221-3240 of 3,900 trials

Recombinant Factor VIIa for Acute Hemorrhagic Stroke

We are studying whether giving a new treatment quickly after a bleeding stroke can improve recovery for patients. This trial focuses on those who have had spontaneous bleeding in the brain and aims to measure their functional outcomes.

Hemorrhagic Stroke>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyNeurology

Scarred Vocal Folds: Autologous Fat Injection Study

We are investigating whether an injection of fat-derived cells can improve voice quality in individuals with scarred vocal folds. This study compares the treatment to a placebo to assess its effectiveness and safety.

Scarred Vocal Folds>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngology

Metformin for Small Abdominal Aortic Aneurysms

We are studying if taking metformin daily can slow the growth of small abdominal aortic aneurysms in patients without diabetes. This trial also looks at the safety and quality of life for participants.

Small Abdominal Aortic Aneurysm>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Ovarian Cancer Relapse: Hyperthermic Intraperitoneal Chemotherapy Study

We are investigating whether adding HIPEC improves survival for patients with ovarian cancer relapse compared to standard treatment. The study also looks at quality of life, side effects, and other important factors.

Ovarian Epithelial Cancer Relapse>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pancreas and Kidney Transplant: Sirolimus vs. Mycophenolate Mofetil

We are comparing two medications to see which one may reduce the risk of hernias after simultaneous pancreas and kidney transplants in people with type 1 diabetes. We also want to understand their effects on diabetes complications.

End-stage Kidney Disease in Type 1 DiabetesTransplantation ComplicationsSimultaneous Pancreas and Kidney Transplantation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal MedicineNephrologyOncologyUrology

Total Hip Replacement: Tranexamic Acid Injection

We are studying whether injecting Tranexamic acid into the hip joint can reduce blood loss during total hip replacement surgery. This trial compares the effects of TXA with a placebo to see which is more effective.

Hip Osteoarthritis>2 yearsEfficacy phase (II)Standard MedicinesHematologyOrthopedics and Traumatology

Dental Implants: Antibiotic Use in Bone Augmentation

We are studying whether short or long-term antibiotic use is more effective during dental implant surgery. This trial will also look at how these antibiotics affect bacteria in the mouth and gut.

Need for Oral Bone Augmentation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Heart Function in Cancer Patients: Nivolumab and Pembrolizumab

We are studying how immunotherapy treatments affect heart function in patients with cancer. This includes monitoring changes in heart performance and rhythm during treatment.

Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyOncology

Improving Ovarian Reserve: rhLH Treatment Study

We are investigating whether a hormone treatment can increase the number of healthy follicles in women trying to conceive. This study aims to assess its effects on fertility and overall safety.

Assisted Fertilization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Sacubitril/Valsartan for Arrhythmogenic Right Ventricular Cardiomyopathy

We are studying whether sacubitril/valsartan can help prevent disease progression in patients with ARVC. This trial aims to assess its effects on heart tissue changes.

Arrhythmogenic Cardiomyopathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Breast Cancer: Palbociclib and Fulvestrant Study

We are investigating if a new treatment combination can help prevent relapse in patients with ER positive HER2 negative breast cancer. This study focuses on those with detectable tumor DNA during treatment.

ER Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HER2 Mutated Solid Tumors: Sevabertinib Study

We are studying how well sevabertinib tablets work and their safety for patients with solid tumors that have HER2 mutations. This research may help improve treatment options for these patients.

Pancreatic CancerUrothelial CarcinomaGallbladder Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineOncology

Chronic Pain After Mastectomy: Comparing Treatments

We are studying the effectiveness of Serratus Plane Block, capsaicin, and botulinum toxin type A for managing chronic neuropathic pain after mastectomy. This trial aims to find out which treatment offers better pain relief for those not helped by standard therapies.

Post-Mastectomy Pain Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOncology

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Congenital Nephrogenic Diabetes Insipidus: Fluconazole Study

We are testing whether fluconazole can help people with congenital nephrogenic diabetes insipidus reduce excessive urination and improve their quality of life. This study focuses on patients with a specific AVPR2 gene mutation.

Congenital Nephrogenic Diabetes Insipidus≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: TAK-881 vs. HYQVIA

We are comparing two medications to see if TAK-881 works similarly to HYQVIA in adults with CIDP. This study may help determine the best treatment options for managing this condition.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Chronic Obstructive Pulmonary Disease: Tezepelumab Study

We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology